Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Anatomical Hepatectomy: A Potential Curative Strategy in Advanced Hepatocellular Carcinoma
Xiaobin Feng,Lin Zhang,Huimin Niu,Hui Zhang,Li Yang,Yong Wen,Steve Y. Chen,Yuhong Shi,Zuoxiang He,Lijuan Yu,Yujun Wang,Xin Huang,Zhiheng Wang,Mengmeng Qin,Xiaoxi Wen,Zhenyu Zhang,Jiyong Song,Zhuozhao Zheng,Hongfang Yin,Huan Zhang,Lijuan Ma,Jixiang Wei,Xinlai Wu,Leida Zhang,Yue Zhao,Qian Lu,Hui Xiao,Tongting Liu,Pihua Fang,Lai Wei,Ripal T. Gandhi,Jiahong Dong
DOI: https://doi.org/10.1111/ajco.13900
2023-01-01
Asia-Pacific Journal of Clinical Oncology
Abstract:About 80% of hepatocellular carcinoma (HCC) patients are in advanced stages and ineligible for curative surgery. Palliative treatments just maintained limited survival, thus an effective downstaging therapy is badly needed. Here we report an initially unresectable patient who underwent radical hepatectomy after successful downstaging with selective internal radiation therapy (SIRT). A 34-year-old man was diagnosed with China Liver Cancer Staging (CNLC) IIIa HCC. Due to insufficient future liver remnant and vascular involvement, the patient was suggested to be unresectable. SIRT with yttrium-90 resin microspheres was given. At three months post-SIRT, a complete response was achieved. The tumor was downstaged to CNLC Ia stage. The patient underwent anatomical hepatectomy 5 months after SIRT. Histopathological examination of the resected specimen showed 4% viable tumor cells inside a necrotic mass. To our knowledge, this is the first case who underwent SIRT with yttrium-90 resin microspheres in China mainland. The success of the downstaging in this case renders a possible cure to be achieved in an initially unresectable patient. In addition, the nearly complete tumor necrosis in the resected specimen indicates a good prognosis post-surgery. This is the first case who underwent SIRT with yttrium-90 resin microspheres in China mainland. SIRT followed by anatomical hepatectomy is a potentially curative strategy for unresectable HCC, which deserves a confirmative trial in the future.